Our Approach

Our development process uniquely relies on quantitative biology in human subjects using advanced stable isotope tracer methodology and kinetic modeling. Our therapeutics are designed to trigger the activation of specific metabolic signaling molecules, modulating enzyme activities, and translation of mRNA. Additionally, the inclusion of key substrates ensures that the modulation of the regulators of metabolic pathways translates to the desired changes in flux through the affected reactions.

Rapid Development

By designing therapies to precisely restore normal flux through disease-affected pathways, we accelerate the development cycle, greatly improve the chances of therapeutic success, and reduce the potential for adverse side effects.

Core Technology

We take advantage of normal biological processes to create desired therapeutic effects by not only modulating the factors controlling key metabolic reactions, but also providing the necessary substrates for the reactions that are activated.

Our Pipeline

Our unique approach lets us target a wide spectrum of diseases which cannot be addressed by current therapies. Predictive algorithmic modelling has shown a high degree of accuracy in forecasting our clinical trial results.

Medicines have traditionally focused on activating the body’s signaling pathways. We are pioneering the next generation of therapeutics that also provide the necessary metabolic substrates for the transcription of mRNA into protein molecules.

Dr. Linda Parks,
United States

World Leaders in
Small Molecule Therapies

Our world-renowned scientific team specializes in the research and development of targeted medical products. Collectively, our team has over 500 peer-reviewed publications and our work been cited by other researchers over 70,000 times.

Therapeutic Areas of Focus

  • Heart Failure
  • Cachexia
  • Obesity
  • Fatty Liver Disease
  • Failure to Thrive

We focus on developing treatments for a wide range of diseases and conditions where our technology provides a clear advantage over competing pharmaceutical treatments. Within each therapeutic area, we develop treatments for specific diseases and symptoms with a focus on improving quality of life, longevity, and overall disease recovery.

Learn More

Areas of ongoing clinical investigations include: heart failure, cachexia, obesity, fatty liver disease, and failure to thrive.